ArticleJTO clinical and research reports2022

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.

Kenji Morimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.